$3.15 Billion is the total value of BB BIOTECH AG's 28 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 17.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corp. | $413,782,000 | +6.2% | 3,750,406 | +0.3% | 13.12% | +24.2% |
| CELG | Buy | Celgene Corp. | $388,254,000 | -5.9% | 3,589,298 | +0.7% | 12.31% | +10.1% |
| RDUS | Buy | Radius Health Inc. | $296,102,000 | +11.5% | 4,272,140 | +8.9% | 9.39% | +30.4% |
| GILD | Buy | Gilead Sciences Inc. | $272,438,000 | -14.3% | 2,774,596 | +2.2% | 8.64% | +0.2% |
| ISIS | Buy | Isis Pharmaceuticals Inc. | $268,180,000 | -21.4% | 6,634,838 | +11.9% | 8.50% | -8.1% |
| ALXN | Buy | Alexion Pharmaceuticals Inc. | $161,774,000 | +15.1% | 1,034,428 | +33.1% | 5.13% | +34.6% |
| AGIO | Buy | Agios Pharmaceuticals Inc. | $148,939,000 | -32.7% | 2,109,921 | +6.0% | 4.72% | -21.2% |
| VRTX | Buy | Vertex Pharmaceuticals Inc. | $142,197,000 | -13.7% | 1,365,445 | +2.3% | 4.51% | +0.9% |
| NBIX | Sell | Neurocrine Biosciences Inc. | $126,196,000 | -18.0% | 3,171,552 | -1.6% | 4.00% | -4.1% |
| MDVN | Buy | Medivation Inc. | $109,697,000 | -25.6% | 2,581,112 | +100.0% | 3.48% | -12.9% |
| REGN | Buy | Regeneron Pharmaceuticals Inc. | $95,354,000 | -5.6% | 205,000 | +3.5% | 3.02% | +10.4% |
| HALO | Buy | Halozyme Therapeutics Inc. | $93,068,000 | -32.2% | 6,929,832 | +14.0% | 2.95% | -20.7% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc. | $91,008,000 | -21.4% | 1,132,499 | +17.3% | 2.89% | -8.0% |
| NVAX | Buy | Novavax Inc. | $58,893,000 | -35.4% | 8,330,000 | +1.8% | 1.87% | -24.4% |
| CLVS | Clovis Oncology Inc. | $56,849,000 | +4.6% | 618,188 | 0.0% | 1.80% | +22.4% | |
| JUNO | Buy | Juno Therapeutics, Inc. | $53,100,000 | +121.3% | 1,305,000 | +190.0% | 1.68% | +158.7% |
| CEMP | Buy | Cempra Inc. | $52,670,000 | -13.2% | 1,891,900 | +7.1% | 1.67% | +1.5% |
| ALDR | Buy | Alder Biopharmaceuticals | $49,473,000 | -19.1% | 1,510,150 | +30.7% | 1.57% | -5.4% |
| TSRO | Buy | Tesaro Inc. | $46,299,000 | -12.9% | 1,154,582 | +27.6% | 1.47% | +1.8% |
| KITE | Buy | Kite Pharma, Inc. | $41,760,000 | +95.7% | 750,000 | +114.3% | 1.32% | +129.1% |
| PBYI | Puma Biotechnology Inc. | $39,337,000 | -35.5% | 521,991 | 0.0% | 1.25% | -24.5% | |
| ICPT | Buy | Intercept Pharmaceuticals | $34,950,000 | -19.9% | 210,719 | +16.6% | 1.11% | -6.3% |
| PTCT | Buy | PTC Therapeutics Inc. | $34,788,000 | -42.3% | 1,302,912 | +4.0% | 1.10% | -32.5% |
| INFI | Infinity Pharmaceuticals Inc. | $22,821,000 | -22.8% | 2,700,737 | 0.0% | 0.72% | -9.7% | |
| ESPR | New | Esperion Therapeutics | $21,433,000 | – | 908,542 | +100.0% | 0.68% | – |
| PRTA | New | Prothena Corp. PLC | $14,509,000 | – | 320,000 | +100.0% | 0.46% | – |
| TTPH | Sell | Tetraphase Pharmaceuticals Inc. | $11,057,000 | -84.5% | 1,482,114 | -1.7% | 0.35% | -81.9% |
| ACHN | Achillion Pharmaceuticals Inc. | $8,840,000 | -22.0% | 1,279,340 | 0.0% | 0.28% | -8.8% | |
| TBPH | Exit | Theravance Biopharma Inc. | $0 | – | -359,190 | -100.0% | -0.13% | – |
| THRX | Exit | Theravance Inc. | $0 | – | -331,594 | -100.0% | -0.16% | – |
| RCPT | Exit | Receptos Inc. | $0 | – | -665,272 | -100.0% | -3.43% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
- Biotech Growth N.V. #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.